Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
Not Applicable
Completed
- Conditions
- Infertility
- Interventions
- Other: Medium Supplemented with Cytochalasin D
- Registration Number
- NCT03677492
- Lead Sponsor
- Ibn Sina Hospital
- Brief Summary
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Cytochalasin D serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Cytochalasin D during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
- ICSI indicated participants
Exclusion Criteria
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Handling Medium Supplemented with Cytochalasin D Medium Supplemented with Cytochalasin D -
- Primary Outcome Measures
Name Time Method Oocyte survival rate 6 days of culture
- Secondary Outcome Measures
Name Time Method Fertilization rate 6 days of culture Embryo utilization rate 6 days of culture Blastocyst formation rate 6 days of culture Ongoing pregnancy rate 12 weeks Clinical pregnancy rate three months Implantation rate 7 weeks
Trial Locations
- Locations (2)
IbnSina IVF Center, IbnSina Hospital
🇪🇬Sohag, Egypt
Banon Assiut
🇪🇬Assiut, Egypt